Hoyer D, Engel G, Kalkman H O
Eur J Pharmacol. 1985 Nov 26;118(1-2):1-12. doi: 10.1016/0014-2999(85)90657-0.
(-)[125I]Iodocyanopindolol ([125I]CYP) labels rat brain membrane sites which display high affinity for several serotonergic and beta-adrenergic compounds. The binding of [125I]CYP to these serotonergic recognition sites was evaluated in the presence of 30 microM (-)isoprenaline in order to suppress binding to beta-adrenoceptors. [125I]CYP binds in rat cortex membranes rapidly, reversibly and stereoselectively to a finite number of recognition sites: Bmax = 180 fmol/mg, KD = 230 pM. Similar affinity values of [125I]CYP were obtained in membranes from rat hippocampus and striatum. Kinetic, saturation and competition experiments suggest that under these conditions [125I]CYP binds to a single serotonergic recognition site named 5-HT1B. The pharmacological profile of 5-HT1B sites is characteristic of a 5-HT1 binding site and shows the following rank order of affinity for agonists: RU 24969, (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]1H-indole) greater than 5-CT, (5-carboxamidotryptamine) greater than 5-HT, (5-hydroxytryptamine, serotonin) greater than 5-OCH3-T, (5-methoxytryptamine) much greater than 2-CH3-5-HT, (2-methylserotonin) greater than 8-OH-DPAT, (8-hydroxy-2-(di-n-pro-pylamino)-tetralin). The rank order of affinity for antagonists is: (+/-)ICYP, ((+/- )-3-I-cyano-pindolol) greater than (-)21-009, (4-[3-ter-butyl-amino-2-hydroxy-propoxy]-indol-2-carbonic acid isopropyl ester) greater than (+)21-009 greater than (-)propranolol greater than metitepin greater than (-)pindolol much greater than ketanserin greater than spiroperidol greater than mesulergine. 5-HT1B recognition sites display low affinity for selective beta 1- and beta 2-adrenoceptor antagonists, e.g. atenolol, betaxolol, ICI 89-406 and ICI 118-551. The low affinity of 5-HT1B recognition sites for some 5-HT1A, 5-HT1C and 5-HT2 selective compounds (e.g. 8-OH-DPAT, mesulergine, ketanserin) suggests that 5-HT1B recognition sites are pharmacologically different from 5-HT1A, 5-HT1C and 5-HT2 recognition sites.
(-)[125I]碘氰吲哚洛尔([125I]CYP)标记大鼠脑膜位点,这些位点对多种血清素能和β-肾上腺素能化合物表现出高亲和力。在存在30微摩尔(-)异丙肾上腺素的情况下评估[125I]CYP与这些血清素能识别位点的结合,以抑制与β-肾上腺素受体的结合。[125I]CYP在大鼠皮层膜中快速、可逆且立体选择性地与有限数量的识别位点结合:最大结合容量(Bmax)=180飞摩尔/毫克,解离常数(KD)=230皮摩尔。在大鼠海马体和纹状体的膜中获得了[125I]CYP的相似亲和力值。动力学、饱和和竞争实验表明,在这些条件下[125I]CYP与一个名为5-HT1B的单一血清素能识别位点结合。5-HT1B位点的药理学特征是5-HT1结合位点的特征,并且对激动剂显示出以下亲和力顺序:RU 24969,(5-甲氧基-3-[1,2,3,6-四氢吡啶-4-基]1H-吲哚)大于5-CT,(5-羧酰胺色胺)大于5-HT,(5-羟色胺,血清素)大于5-OCH3-T,(5-甲氧基色胺)远大于2-CH3-5-HT,(2-甲基血清素)大于8-OH-DPAT,(8-羟基-2-(二正丙基氨基)-四氢萘)。对抗拮抗剂的亲和力顺序是:(±)ICYP,((±)-3-I-氰基吲哚洛尔)大于(-)21-009,(4-[3-叔丁基氨基-2-羟基丙氧基]-吲哚-2-碳酸异丙酯)大于(+)21-009大于(-)普萘洛尔大于甲替平大于(-)吲哚洛尔远大于酮色林大于螺哌啶醇大于美舒麦角。5-HT1B识别位点对选择性β1和β2肾上腺素受体拮抗剂,如阿替洛尔、倍他洛尔、ICI 89-406和ICI 118-551显示出低亲和力。5-HT1B识别位点对一些5-HT1A、5-HT1C和5-HT2选择性化合物(如8-OH-DPAT、美舒麦角、酮色林)表现出低亲和力,这表明5-HT1B识别位点在药理学上与5-HT1A、5-HT1C和5-HT2识别位点不同。